Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

Inbal Braunstein, Tara C. Gangadhar, Rosalie Elenitsas, Emily Y. Chu

Research output: Contribution to journalArticle

Abstract

Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.

Original languageEnglish (US)
Pages (from-to)539-543
Number of pages5
JournalJournal of Cutaneous Pathology
Volume41
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Dermatitis
Proto-Oncogene Proteins B-raf
Radiodermatitis
Radiation
Mitogen-Activated Protein Kinases
Protein Kinases
Melanoma
Mutation
Therapeutics
Burnett Schwartz Berberian syndrome
PLX4032

Keywords

  • dermatopathology
  • melanoma
  • radiation therapy

ASJC Scopus subject areas

  • Dermatology
  • Pathology and Forensic Medicine
  • Histology
  • Medicine(all)

Cite this

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption. / Braunstein, Inbal; Gangadhar, Tara C.; Elenitsas, Rosalie; Chu, Emily Y.

In: Journal of Cutaneous Pathology, Vol. 41, No. 6, 2014, p. 539-543.

Research output: Contribution to journalArticle

@article{73731703fef34c2eb3dcaadf5d7a6c81,
title = "Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption",
abstract = "Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.",
keywords = "dermatopathology, melanoma, radiation therapy",
author = "Inbal Braunstein and Gangadhar, {Tara C.} and Rosalie Elenitsas and Chu, {Emily Y.}",
year = "2014",
doi = "10.1111/cup.12318",
language = "English (US)",
volume = "41",
pages = "539--543",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

AU - Braunstein, Inbal

AU - Gangadhar, Tara C.

AU - Elenitsas, Rosalie

AU - Chu, Emily Y.

PY - 2014

Y1 - 2014

N2 - Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.

AB - Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.

KW - dermatopathology

KW - melanoma

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84901586561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901586561&partnerID=8YFLogxK

U2 - 10.1111/cup.12318

DO - 10.1111/cup.12318

M3 - Article

C2 - 24517243

AN - SCOPUS:84901586561

VL - 41

SP - 539

EP - 543

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

IS - 6

ER -